These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 31550069)

  • 1. A prospective, iterative, adaptive trial of carfilzomib-based desensitization.
    Tremblay S; Driscoll JJ; Rike-Shields A; Hildeman DA; Alloway RR; Girnita AL; Brailey PA; Woodle ES
    Am J Transplant; 2020 Feb; 20(2):411-421. PubMed ID: 31550069
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pretransplant Desensitization with Costimulation Blockade and Proteasome Inhibitor Reduces DSA and Delays Antibody-Mediated Rejection in Highly Sensitized Nonhuman Primate Kidney Transplant Recipients.
    Ezekian B; Schroder PM; Mulvihill MS; Barbas A; Collins B; Freischlag K; Yoon J; Yi JS; Smith F; Olaso D; Saccoccio FM; Permar S; Farris AB; Kwun J; Knechtle SJ
    J Am Soc Nephrol; 2019 Dec; 30(12):2399-2411. PubMed ID: 31658991
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Prospective iterative trial of proteasome inhibitor-based desensitization.
    Woodle ES; Shields AR; Ejaz NS; Sadaka B; Girnita A; Walsh RC; Alloway RR; Brailey P; Cardi MA; Abu Jawdeh BG; Roy-Chaudhury P; Govil A; Mogilishetty G
    Am J Transplant; 2015 Jan; 15(1):101-18. PubMed ID: 25534446
    [TBL] [Abstract][Full Text] [Related]  

  • 4. 32 Doses of Bortezomib for Desensitization Is Not Well Tolerated and Is Associated With Only Modest Reductions in Anti-HLA Antibody.
    Moreno Gonzales MA; Gandhi MJ; Schinstock CA; Moore NA; Smith BH; Braaten NY; Stegall MD
    Transplantation; 2017 Jun; 101(6):1222-1227. PubMed ID: 27379560
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bortezomib for refractory acute antibody-mediated rejection in kidney transplant recipients: A single-centre case series.
    De Sousa-Amorim E; Revuelta I; Diekmann F; Cofan F; Lozano M; Cid J; Palou E; Sole M; Campistol JM; Oppenheimer F
    Nephrology (Carlton); 2016 Aug; 21(8):700-4. PubMed ID: 26492594
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Treatment of Biopsy-Proven Acute Antibody-Mediated Rejection Using Thymoglobulin (ATG) Monotherapy and a Combination of Rituximab, Intravenous Immunoglobulin, and Plasmapheresis: Lesson Learned from Primary Experience.
    Zheng J; Xue W; Qing X; Jing X; Hou J; Tian X; Guo Q; He X; Cai J
    Clin Transpl; 2014; ():223-30. PubMed ID: 26281149
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of carfilzomib-based desensitization on heart transplantation of sensitized candidates.
    Sriwattanakomen R; Xu Q; Demehin M; Shullo MA; Mangiola M; Hickey GW; Sciortino CM; Horn ET; Keebler ME; Zeevi A
    J Heart Lung Transplant; 2021 Jul; 40(7):595-603. PubMed ID: 33785250
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Combination of Total Lymphoid Irradiation, Low-Dose IVIG and ATG as Rescue Therapy for Highly Sensitized and Antibody-Mediated Rejection Renal Transplant Recipients.
    Zhu D; Qi G; Tang Q; Li L; Yang C; Lin M; Wu B; Xu M; Cai J; Zhu T; Rong R
    Clin Transpl; 2014; ():215-21. PubMed ID: 26281148
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Results of a multicenter prospective clinical study in Japan for evaluating efficacy and safety of desensitization protocol based on rituximab in ABO-incompatible kidney transplantation.
    Takahashi K; Saito K; Takahara S; Fuchinoue S; Yagisawa T; Aikawa A; Watarai Y; Yoshimura N; Tanabe K; Morozumi K; Shimazu M;
    Clin Exp Nephrol; 2017 Aug; 21(4):705-713. PubMed ID: 27534951
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Successful kidney transplantation after desensitization using plasmapheresis, low-dose intravenous immunoglobulin, and rituximab in highly sensitized patients: a single-center experience.
    Jin MK; Cho JH; Kwon O; Hong KD; Choi JY; Yoon SH; Park SH; Kim YL; Kim CD
    Transplant Proc; 2012 Jan; 44(1):200-3. PubMed ID: 22310614
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Once weekly versus twice weekly carfilzomib dosing in patients with relapsed and refractory multiple myeloma (A.R.R.O.W.): interim analysis results of a randomised, phase 3 study.
    Moreau P; Mateos MV; Berenson JR; Weisel K; Lazzaro A; Song K; Dimopoulos MA; Huang M; Zahlten-Kumeli A; Stewart AK
    Lancet Oncol; 2018 Jul; 19(7):953-964. PubMed ID: 29866475
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Proteasomal adaptations underlying carfilzomib-resistance in human bone marrow plasma cells.
    Woodle ES; Tremblay S; Brailey P; Girnita A; Alloway RR; Aronow B; Dasgupta N; Ebstein F; Kloetzel PM; Lee MJ; Kim KB; Singh H; Driscoll JJ
    Am J Transplant; 2020 Feb; 20(2):399-410. PubMed ID: 31595669
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Panel-reactive antibody levels and renal transplantation rates in sensitized patients after desensitization and human leucocyte antigen amino acid residue matching.
    Shang W; Dong L; Feng G; Wang Y; Pang X; Li J; Liu L; Zhang W
    J Int Med Res; 2013 Aug; 41(4):1333-41. PubMed ID: 23780877
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy of immunoadsorption to reduce donor-specific alloantibodies in kidney-transplant candidates.
    Rostaing L; Congy N; Aarnink A; Maggioni S; Allal A; Sallusto F; Game X; Kamar N
    Exp Clin Transplant; 2015 Apr; 13 Suppl 1():201-6. PubMed ID: 25894155
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Prognostic tools to assess candidacy for and efficacy of antibody-removal therapy.
    Pinelli DF; Zachary AA; Friedewald JJ; Gjertson DW; Evans MA; Chatroop EN; Leffell MS; Vo AA; Jordan SC; Montgomery RA; Tambur AR
    Am J Transplant; 2019 Feb; 19(2):381-390. PubMed ID: 29981209
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bortezomib as an adjuvant to conventional therapy in the treatment of antibody mediated rejection (AMR): the full spectrum.
    Al Meshari K; Pall A; Elgamal H; Alzayer F; Altalhi M
    Clin Transpl; 2010; ():383-90. PubMed ID: 21696055
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Durability of antibody removal following proteasome inhibitor-based therapy.
    Everly MJ; Terasaki PI; Trivedi HL
    Transplantation; 2012 Mar; 93(6):572-7. PubMed ID: 22262128
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Desensitization and renal transplant: plasmapheresis/IVIG standard dose in patients with high immunological risk.
    Flores-Gama F; Mondragón-Ramírez GA; Bochicchio-Riccardelli T
    Cir Cir; 2009; 77(5):369-74. PubMed ID: 19944025
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transplanting Sensitized Kidney Transplant Patients With Equivalent Outcomes Utilizing Stringent HLA Crossmatching.
    Rohan VS; Taber DJ; Moussa O; Pilch NA; Denmark S; Meadows HB; McGillicuddy JW; Chavin KD; Baliga PK; Bratton CF
    Exp Clin Transplant; 2017 Feb; 15(1):47-55. PubMed ID: 27267614
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Kidney transplant in highly sensitized patients after desensitization with plasmapheresis and low-dose intravenous immunoglobulin.
    Yuan XP; Wang CX; Gao W; Fu Q; He XS
    Exp Clin Transplant; 2010 Jun; 8(2):130-5. PubMed ID: 20565369
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.